VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer

Journal article

Open access

Peer reviewed

I. B. Vergote, A. Pyrez Fidalgo, E. Hamilton, G. Valabrega, T. Van Gorp, J. Sehouli, D. Cibula, T. Levy, S. Welch, D. L. Richardson, …

Annals of oncology, Vol.33(4), pp.448-450

04/01/2022

Abstract

Life Sciences & Biomedicine

Oncology

Science & Technology

url

https://doi.org/10.1016/j.annonc.2022.02.223View

Published (Version of record) Open

1 Record Views

Title: VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer
Creators: I. B. Vergote - Universitair Ziekenhuis Leuven
A. Pyrez Fidalgo - College Station Medical Center
E. Hamilton - Tennessee Oncology
G. Valabrega - University of Turin
T. Van Gorp - KU Leuven
J. Sehouli - Charité - Universitätsmedizin Berlin
D. Cibula - General University Hospital in Prague
T. Levy - Wolfson Medical Center
S. Welch - London Health Sciences Centre
D. L. Richardson - University of Oklahoma
E. M. Guerra Alia - Hospital Universitario Ramón y Cajal
G. Scambia - Agostino Gemelli University Polyclinic
S. Henry - UCLouvain
P. Wimberger - University Hospital Carl Gustav Carus
D. Miller - The University of Texas Southwestern Medical Center
J. Martinez - GEICO, Dept Oncol, Murcia, Spain
B. J. Monk - Creighton University
S. Shacham - Karyopharm Therapeutics
M. R. Mirza - Karyopharm Therapeutics
V. Makker - Memorial Sloan Kettering Cancer Center
Publication Details: Annals of oncology, Vol.33(4), pp.448-450
Publisher: Elsevier
Number of pages: 3
Grant note: Karyopharm Therapeutics
Identifiers: 991005968888802656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article